Literature DB >> 15494351

This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis.

C Gorman1, A Bhatia, A Rahman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494351     DOI: 10.1093/rheumatology/keh440

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  1 in total

1.  Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide.

Authors:  Hee-Jin Park; Mi-Il Kang; Yoon Kang; Soo-Jin Chung; Sang-Won Lee; Yong-Beom Park; Soo-Kon Lee
Journal:  J Korean Med Sci       Date:  2013-03-04       Impact factor: 2.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.